Li, L., Karanika, S., Yang, G., Wang, J., Park, S., Broom, B., . . . Thompson, T. C. (2017). Enzalutamide-induced “BRCAness” and PARP inhibition is a synthetic lethal therapy for castration-resistant prostate cancer. Sci Signal.
استشهاد بنمط شيكاغوLi, Likun, et al. "Enzalutamide-induced “BRCAness” and PARP Inhibition Is a Synthetic Lethal Therapy for Castration-resistant Prostate Cancer." Sci Signal 2017.
MLA استشهادLi, Likun, et al. "Enzalutamide-induced “BRCAness” and PARP Inhibition Is a Synthetic Lethal Therapy for Castration-resistant Prostate Cancer." Sci Signal 2017.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.